Cargando…

Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III

Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase in tissue density in follow-up CTs. Hence, the stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Stana, Markus, Grambozov, Brane, Gaisberger, Christoph, Karner, Josef, Ruznic, Elvis, Berchtold, Johannes, Zellinger, Barbara, Moosbrugger, Raphaela, Studnicka, Michael, Fastner, Gerd, Sedlmayer, Felix, Zehentmayr, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139430/
https://www.ncbi.nlm.nih.gov/pubmed/35626183
http://dx.doi.org/10.3390/diagnostics12051027
_version_ 1784714857340207104
author Stana, Markus
Grambozov, Brane
Gaisberger, Christoph
Karner, Josef
Ruznic, Elvis
Berchtold, Johannes
Zellinger, Barbara
Moosbrugger, Raphaela
Studnicka, Michael
Fastner, Gerd
Sedlmayer, Felix
Zehentmayr, Franz
author_facet Stana, Markus
Grambozov, Brane
Gaisberger, Christoph
Karner, Josef
Ruznic, Elvis
Berchtold, Johannes
Zellinger, Barbara
Moosbrugger, Raphaela
Studnicka, Michael
Fastner, Gerd
Sedlmayer, Felix
Zehentmayr, Franz
author_sort Stana, Markus
collection PubMed
description Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase in tissue density in follow-up CTs. Hence, the study aim was to correlate the dynamics in radiographic alterations to carbon monoxide diffusing capacity (DL [Formula: see text]) and FEV [Formula: see text] , which may contribute to a better understanding of radiation-induced lung disease. Methods: Eighty-five patients with NSCLC III were included. All of them received two cycles of platinum-based induction chemotherapy followed by high dose radiation. Thereafter, durvalumab was administered for one year in 63/85 patients (74%). Pulmonary function tests (PFTs) were performed three months and six months after completion of radiotherapy (RT) and compared to baseline. At the same time points, patients underwent diagnostic CT (dCT). These dCTs were matched to the planning CT (pCT) using RayStation(®) Model Based Segmentation and deformable image registration. Differential volumes defined by specific isodoses were generated to correlate them with the PFTs. Results: In general, significant correlations between PFTs and differential volumes were found in the mid-dose range, especially for the volume of the lungs receiving between 65% and 45% of the dose prescribed (V [Formula: see text]) and DL [Formula: see text] ([Formula: see text]). This volume range predicted DL [Formula: see text] after RT (p-value 0.03) as well. In multivariate analysis, DL [Formula: see text] (p-value 0.040) and FEV [Formula: see text] (p-value 0.014) predicted pneumonitis. Conclusions: The current analysis revealed a strong relation between the dynamics of DL [Formula: see text] and CT morphology changes in the mid-dose range, which convincingly indicates the importance of routinely used PFTs in the context of a curative treatment approach.
format Online
Article
Text
id pubmed-9139430
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91394302022-05-28 Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III Stana, Markus Grambozov, Brane Gaisberger, Christoph Karner, Josef Ruznic, Elvis Berchtold, Johannes Zellinger, Barbara Moosbrugger, Raphaela Studnicka, Michael Fastner, Gerd Sedlmayer, Felix Zehentmayr, Franz Diagnostics (Basel) Article Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase in tissue density in follow-up CTs. Hence, the study aim was to correlate the dynamics in radiographic alterations to carbon monoxide diffusing capacity (DL [Formula: see text]) and FEV [Formula: see text] , which may contribute to a better understanding of radiation-induced lung disease. Methods: Eighty-five patients with NSCLC III were included. All of them received two cycles of platinum-based induction chemotherapy followed by high dose radiation. Thereafter, durvalumab was administered for one year in 63/85 patients (74%). Pulmonary function tests (PFTs) were performed three months and six months after completion of radiotherapy (RT) and compared to baseline. At the same time points, patients underwent diagnostic CT (dCT). These dCTs were matched to the planning CT (pCT) using RayStation(®) Model Based Segmentation and deformable image registration. Differential volumes defined by specific isodoses were generated to correlate them with the PFTs. Results: In general, significant correlations between PFTs and differential volumes were found in the mid-dose range, especially for the volume of the lungs receiving between 65% and 45% of the dose prescribed (V [Formula: see text]) and DL [Formula: see text] ([Formula: see text]). This volume range predicted DL [Formula: see text] after RT (p-value 0.03) as well. In multivariate analysis, DL [Formula: see text] (p-value 0.040) and FEV [Formula: see text] (p-value 0.014) predicted pneumonitis. Conclusions: The current analysis revealed a strong relation between the dynamics of DL [Formula: see text] and CT morphology changes in the mid-dose range, which convincingly indicates the importance of routinely used PFTs in the context of a curative treatment approach. MDPI 2022-04-19 /pmc/articles/PMC9139430/ /pubmed/35626183 http://dx.doi.org/10.3390/diagnostics12051027 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stana, Markus
Grambozov, Brane
Gaisberger, Christoph
Karner, Josef
Ruznic, Elvis
Berchtold, Johannes
Zellinger, Barbara
Moosbrugger, Raphaela
Studnicka, Michael
Fastner, Gerd
Sedlmayer, Felix
Zehentmayr, Franz
Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
title Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
title_full Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
title_fullStr Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
title_full_unstemmed Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
title_short Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
title_sort carbon monoxide diffusing capacity (dl(co)) correlates with ct morphology after chemo-radio-immunotherapy for non-small cell lung cancer stage iii
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139430/
https://www.ncbi.nlm.nih.gov/pubmed/35626183
http://dx.doi.org/10.3390/diagnostics12051027
work_keys_str_mv AT stanamarkus carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT grambozovbrane carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT gaisbergerchristoph carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT karnerjosef carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT ruznicelvis carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT berchtoldjohannes carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT zellingerbarbara carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT moosbruggerraphaela carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT studnickamichael carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT fastnergerd carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT sedlmayerfelix carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii
AT zehentmayrfranz carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii